deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04814875

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Sponsor: Novotech (Australia) Pty Limited

Conditions Fallopian Tube Cancer High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer Ovarian Cancer Primary Peritoneal Carcinoma
Interventions ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
Updated 7 times since 2021 Last updated: Feb 13, 2024 Started: Sep 1, 2021 Primary completion: Nov 30, 2023 Completion: Nov 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM ATX101-03, immediately.

Other terminated trials from Novotech (Australia) Pty Limited

More terminations from Novotech (Australia) Pty Limited

Other Fallopian Tube Cancer trials with similar outcome

Browse all Fallopian Tube Cancer trials

A PHASE1/PHASE2 clinical study on Fallopian Tube Cancer and High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer, this trial is terminated or withdrawn. The trial is conducted by Novotech (Australia) Pty Limited and has accumulated 7 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2024 · 15 months · monthly snapshotRecruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  4. Dec 2022 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  2. Apr 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novotech (Australia) Pty Limited
  • THERAPIM PTY LTD
Data source: THERAPIM PTY LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations